What is the formula to calculate the FIB-4 (Fibrosis-4) score?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

FIB-4 Score Calculation Formula

The FIB-4 score is calculated using the formula: Age (years) × AST (IU/L) / [Platelet count (×10⁹/L) × √ALT (IU/L)] 1.

Required Laboratory Values

To calculate FIB-4, you need four specific values:

  • Age in years 1
  • AST (aspartate aminotransferase) in IU/L or U/L 1
  • ALT (alanine aminotransferase) in IU/L or U/L 1
  • Platelet count in ×10⁹/L (or multiply by 10⁹ if given in standard units) 1

Step-by-Step Calculation

  1. Multiply the patient's age by their AST level 1
  2. Calculate the square root of the ALT value 1
  3. Multiply the platelet count by the square root of ALT 1
  4. Divide the result from step 1 by the result from step 3 1

Interpretation of Results

Standard Cutoff Values (Adults <65 years)

  • FIB-4 <1.3 (or <1.45): Low probability of advanced fibrosis, with a negative predictive value of approximately 90% for advanced fibrosis 1, 2
  • FIB-4 1.3-2.67 (or 1.45-3.25): Indeterminate range requiring additional testing such as elastography or Enhanced Liver Fibrosis (ELF) testing 1
  • FIB-4 >2.67 (or >3.25): High probability of advanced fibrosis, with a positive predictive value of approximately 65% for advanced fibrosis 1

Age-Adjusted Cutoffs (≥65 years)

  • For patients aged 65 years or older, use a higher threshold of FIB-4 >2.0 instead of >1.3 to reduce false positives, as FIB-4 naturally increases with age 1, 3

Age-Specific Cutoffs for NAFLD (Validated in Japanese Cohort)

  • Age ≤49 years: Low cutoff 1.05, high cutoff 1.21 3
  • Age 50-59 years: Low cutoff 1.24, high cutoff 1.96 3
  • Age 60-69 years: Low cutoff 1.88, high cutoff 2.67 3
  • Age ≥70 years: Low cutoff 1.95, high cutoff 2.67 3

Clinical Performance

  • FIB-4 has an AUROC of approximately 0.77-0.86 for detecting advanced fibrosis, depending on the population studied 1, 2
  • The test performs best at ruling out advanced fibrosis (high negative predictive value) rather than confirming it 1, 2
  • FIB-4 may miss approximately 10% of patients with advanced fibrosis even when below the low cutoff 1
  • Serial FIB-4 measurements can track fibrosis progression: An increase in FIB-4 of ≥0.4 per year predicts progression to cirrhosis with an AUROC of 0.910 4

Important Limitations

  • FIB-4 has limited accuracy in the intermediate range (1.3-2.67), where approximately 30-40% of patients fall, necessitating additional testing 1
  • Age significantly affects FIB-4 values: The score naturally increases with age, leading to higher false-positive rates in elderly patients and potential false-negatives in younger patients 1, 3
  • Performance varies by underlying liver disease: FIB-4 was originally validated in hepatitis C/HIV co-infection but is now widely used in NAFLD, hepatitis B, and other chronic liver diseases 1, 4
  • Diabetes and metabolic syndrome may reduce diagnostic accuracy in NAFLD populations 1

Clinical Application Algorithm

When FIB-4 is <1.3 (or <2.0 if age ≥65):

  • Advanced fibrosis is unlikely 1
  • Repeat testing every 1-3 years in at-risk populations 1
  • No immediate need for elastography or liver biopsy 1

When FIB-4 is 1.3-2.67 (indeterminate):

  • Proceed to liver elastography (FibroScan, VCTE) as second-line test 1
  • Alternative: Implement 1-year lifestyle intervention and retest; if still elevated, proceed to elastography 1
  • Consider ELF testing as alternative to elastography 1

When FIB-4 is >2.67 (or >3.25):

  • High probability of advanced fibrosis 1
  • Refer to hepatology for comprehensive evaluation 1
  • Consider elastography or liver biopsy for confirmation and staging 1
  • Initiate surveillance for hepatocellular carcinoma and portal hypertension complications 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.